134 related articles for article (PubMed ID: 10918629)
1. Does cyclosporin A generate free radicals?
Buetler TM; Cottet-Maire F; Krauskopf A; Ruegg UT
Trends Pharmacol Sci; 2000 Aug; 21(8):288-90. PubMed ID: 10918629
[No Abstract] [Full Text] [Related]
2. Cyclosporin A and free radical generation.
Paolini M; Biagi GL; Cantelli-Forti G
Trends Pharmacol Sci; 2001 Jan; 22(1):14-6. PubMed ID: 11252260
[No Abstract] [Full Text] [Related]
3. Cyclosporin A-induced free radical generation is not mediated by cytochrome P-450.
Krauskopf A; Buetler TM; Nguyen NS; Macé K; Ruegg UT
Br J Pharmacol; 2002 Feb; 135(4):977-86. PubMed ID: 11861326
[TBL] [Abstract][Full Text] [Related]
4. Oxygen radical formation due to the effect of varying hydrogen ion concentrations on cytochrome P450-catalyzed cyclosporine metabolism in rat and human liver microsomes.
Ahmed SS; Napoli KL; Strobel HW
Adv Exp Med Biol; 1996; 387():135-9. PubMed ID: 8794205
[No Abstract] [Full Text] [Related]
5. Oxygen radical formation during cytochrome P450-catalyzed cyclosporine metabolism in rat and human liver microsomes at varying hydrogen ion concentrations.
Ahmed SS; Napoli KL; Strobel HW
Mol Cell Biochem; 1995 Oct; 151(2):131-40. PubMed ID: 8569758
[TBL] [Abstract][Full Text] [Related]
6. Generation of oxygen free radicals during the metabolism of cyclosporine A: a cause-effect relationship with metabolism inhibition.
Serino F; Grevel J; Napoli KL; Kahan BD; Strobel HW
Mol Cell Biochem; 1993 May; 122(2):101-12. PubMed ID: 8232241
[TBL] [Abstract][Full Text] [Related]
7. Metabolism-dependent stimulation of reactive oxygen species and DNA synthesis by cyclosporin A in rat smooth muscle cells.
Nguyen NS; Cottet-Maire F; Buetler TM; Lo Russo A; Krauskopf AS; Armstrong JM; Vickers AE; Macé K; Rüegg UT
Free Radic Biol Med; 1999 Dec; 27(11-12):1267-75. PubMed ID: 10641720
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450.
Pichard L; Domergue J; Fourtanier G; Koch P; Schran HF; Maurel P
Biochem Pharmacol; 1996 Mar; 51(5):591-8. PubMed ID: 8615894
[TBL] [Abstract][Full Text] [Related]
9. [Glucose intolerance induced by tacrolimus (FK506), cyclosporin A].
Ueda K; Tanizawa Y
Nihon Rinsho; 2005 Feb; 63 Suppl 2():333-7. PubMed ID: 15779398
[No Abstract] [Full Text] [Related]
10. Oxidative stress in cyclosporin and azathioprine treated renal transplant patients.
McGrath LT; Treacy R; McClean E; Brown JH
Clin Chim Acta; 1997 Aug; 264(1):1-12. PubMed ID: 9267698
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs.
Lytton SD; Berg U; Nemeth A; Ingelman-Sundberg M
Clin Exp Immunol; 2002 Feb; 127(2):293-302. PubMed ID: 11876753
[TBL] [Abstract][Full Text] [Related]
12. Interactions of cyclosporin A and amlodipine: blood cyclosporin A levels, hypertension and kidney function.
Schrama YC; Koomans HA
J Hypertens Suppl; 1998 Sep; 16(4):S33-8. PubMed ID: 9817190
[TBL] [Abstract][Full Text] [Related]
13. Metabolic dependence of cyclosporine A on cell proliferation of human non‑small cell lung cancer A549 cells and its implication in post‑transplant malignancy.
Qin X; Chen Z
Oncol Rep; 2019 May; 41(5):2997-3004. PubMed ID: 30896878
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporin neurotoxicity after chemotherapy. Cyclosporin causes reversible posterior leukoencephalopathy syndrome.
Lewis MB
BMJ; 1999 Jul; 319(7201):54-5. PubMed ID: 10523082
[No Abstract] [Full Text] [Related]
15. The effect of immunosuppressive agents (FK-506, rapamycin) on renal P450 systems in rat models.
Yoshimura R; Yoshimura N; Ohyama A; Ohmachi T; Yamamoto K; Kishimoto T; Wada S
J Pharm Pharmacol; 1999 Aug; 51(8):941-8. PubMed ID: 10504034
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporin A.
National Toxicology Program
Rep Carcinog; 2011; 12():125-7. PubMed ID: 21850137
[No Abstract] [Full Text] [Related]
17. Complications of cyclosporin therapy.
Hoyer PF
Contrib Nephrol; 1995; 114():111-23. PubMed ID: 7587195
[No Abstract] [Full Text] [Related]
18. The determination of metabolite M17 and its meaning for immunosuppressive cyclosporin therapy.
Khoschsorur G; Auer T; Lanzer G; Petritsch P; Holzer H; Tscheliessnigg KH
Angiology; 1998 Apr; 49(4):307-14. PubMed ID: 9555934
[TBL] [Abstract][Full Text] [Related]
19. Morphologic features of cyclosporin nephrotoxicity.
D'Agati VD
Contrib Nephrol; 1995; 114():84-110. PubMed ID: 7587203
[No Abstract] [Full Text] [Related]
20. Use of rapamycin in a transplant patient who developed cyclosporin neurotoxicity.
Hodges CB; Maxwell H; Beattie TJ; Murphy AV; Jindal RM
Pediatr Nephrol; 2001 Oct; 16(10):777-8. PubMed ID: 11605780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
